Journey Biosciences has developed an innovative blood test called NaviDKD®, designed to predict the risk of kidney disease in individuals with diabetes, well before any symptoms manifest. This proactive approach allows patients to take control of their health by identifying their risk levels and receiving personalized prevention strategies. The test is based on well-researched blood markers, particularly focusing on Advanced Glycation End Products (AGEs), which have been identified as significant predictors of kidney disease onset. By measuring these biomarkers, NaviDKD® enables precise risk assessment and timely interventions, potentially reducing the likelihood of serious complications associated with diabetes-related kidney disease.

The scientific foundation of Journey Biosciences is rooted in extensive research led by Dr. Paul Beisswenger, a co-founder and expert in endocrinology. His work has highlighted the critical role of AGEs in the progression of kidney disease, particularly in diabetic patients. The company’s commitment to preventive health solutions is underscored by clinical studies that validate the association between elevated AGEs and kidney disease onset. By leveraging these insights, Journey Biosciences aims to provide effective screening tools that empower individuals to manage their health proactively, ultimately preserving their quality of life and reducing the need for invasive treatments.

United States

✨ Journey Biosciences is on a mission to shift the future of care.

🧬 Our flagship solution blends the precision of NaviDKD®, a clinically-validated predictive screening, with the AI-driven insights of Compass™, to offer up to 12 years of advanced diabetes-related kidney disease (DKD) detection, plus tailored intervention strategies to slow or prevent progression.

🎯 This approach improves patient outcomes, optimizes resource allocation, and reduces costs. 

🔍 Discover more about our transformative approach at journeybio.life.

Journey Biosciences

Company Details